Publication number: 20230113037
Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
Type:
Application
Filed:
August 10, 2020
Publication date:
April 13, 2023
Applicants:
Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUM
Inventors:
Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
Publication number: 20160009725
Abstract: What is described are BET protein-inhibitory, especially BRD2-, BRD3- and BRD4-inhibitory, bicyclo- and spino-substituted pyrrolo- and pyrazolodiazepines of the general formula I in which X, Y, n, m, R1, R2, R3, R4 and R5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as BET protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control.
Type:
Application
Filed:
February 17, 2014
Publication date:
January 14, 2016
Applicant:
BAYER PHARMA AKTIENGESELLSCHAFT
Inventors:
Norbert SCHMEES, Bernd BUCHMANN, Bernard HAENDLER, Roland NEUHAUS, Pascale LEJEUNE, Martin KRÜGER, Amaury Ernesto FERNANDEZ-MONTALVAN, Hermann KÜNZER